Robert F. Kennedy Jr.’s HHS to end COVID-19 emergency use authorizations for drugs and medical devices
Robert F. Kennedy Jr. Image Credit: Getty Images
The U.S. Department of Health and Human Services (HHS) has announced plans to phase out key COVID-19 Emergency Use Authorization (EUA) declarations, marking another significant step away from pandemic-era regulatory measures.
The decision, announced on June 30, 2026, will end the special emergency declarations that have allowed certain COVID-19 drugs, biological products, and medical devices to receive expedited authorization since the height of the pandemic in 2020.
According to HHS, the public health circumstances that originally justified these emergency authorizations “no longer exist,” prompting the department to establish a timeline for winding down the emergency framework.
The move comes under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr. and represents one of the most notable regulatory changes affecting COVID-19 medical products since federal public health emergency policies began to expire.
HHS Sets Timeline for Ending Emergency Use Authorizations
Under the announcement, HHS will end Emergency Use Authorization declarations on two separate dates:
- Medical devices: EUA declaration expires December 26, 2026
- Drugs and biological products: EUA declaration ends June 29, 2027
These declarations were originally issued in 2020 to accelerate access to critical medical products during the COVID-19 pandemic when no fully approved alternatives were widely available.
Once the declarations expire, manufacturers seeking authorization for future products will generally need to rely on the FDA’s standard regulatory pathways unless another public health emergency is declared.
What Are Emergency Use Authorizations?
Emergency Use Authorizations are special regulatory tools that allow the U.S. Food and Drug Administration (FDA) to make certain medical products available during public health emergencies before completing the traditional approval process.
Throughout the COVID-19 pandemic, EUAs enabled rapid access to:
- Antiviral medications
- Diagnostic tests
- Ventilators
- Medical monitoring devices
- Personal protective equipment
- Certain biological therapies
The policy played a central role in expanding healthcare capacity during the pandemic while allowing new treatments and technologies to reach patients more quickly.
Why HHS Is Ending the Emergency Declarations
HHS said the decision reflects the significant improvement in the nation’s public health situation compared with the early stages of the COVID-19 pandemic.
According to the department, the emergency conditions that justified expedited regulatory authority have largely passed.
By ending the declarations, federal regulators are signaling a transition back toward normal oversight procedures for COVID-19 medical products.
The announcement does not indicate that existing FDA-approved medicines or permanently authorized medical products will be removed from the market.
READ ALSO
New ‘Cicada’ COVID Variant BA.3.2 spreads in the US: Symptoms, vaccine concerns and what WHO says
What the Changes Mean for Healthcare Providers
Hospitals, healthcare systems, and manufacturers will have a transition period before the emergency declarations officially expire.
Medical device manufacturers have until December 2026 to prepare for the end of emergency authorization policies, while pharmaceutical and biotechnology companies have until June 2027.
Healthcare providers are expected to continue using FDA-approved COVID-19 therapies and devices under existing regulatory standards.
Products that already received full FDA approval will not be affected by the expiration of the emergency declarations.
Will COVID-19 Treatments Still Be Available?
Yes. The announcement does not mean COVID-19 treatments or medical devices will disappear.
Instead, it marks the end of the legal emergency framework that allowed faster authorization during the pandemic.
FDA-approved treatments, vaccines, and medical devices can continue to be prescribed and distributed under normal regulatory processes.
Future products seeking authorization, however, will generally need to satisfy standard FDA approval requirements rather than relying on emergency authorization.
A Shift Toward Post-Pandemic Regulation
The expiration of COVID-19 Emergency Use Authorizations reflects the federal government’s broader transition away from pandemic-era emergency policies.
Since 2023, many temporary COVID-19 emergency measures have gradually been phased out as vaccines, treatments, healthcare capacity, and disease management improved.
The latest HHS action continues that process by establishing final expiration dates for emergency authorization declarations covering medical products.
Healthcare organizations are expected to use the transition period to ensure compliance with standard FDA regulatory requirements before the declarations officially expire.
What Happens Next?
Medical device manufacturers, pharmaceutical companies, hospitals, and healthcare providers now have several months, and in some cases nearly a year, to prepare for the regulatory transition.
Federal agencies are expected to continue providing guidance as the expiration dates approach.
Unless a new public health emergency is declared, the Emergency Use Authorization framework established for COVID-19 products will formally come to an end according to the announced timeline.
FAQ
What did HHS announce about COVID-19 Emergency Use Authorizations?
HHS announced it will end Emergency Use Authorization declarations for certain COVID-19 drugs, biological products, and medical devices because the emergency conditions that justified them no longer exist.
When will the Emergency Use Authorizations end?
Medical device EUA declarations will expire on December 26, 2026, while declarations covering drugs and biological products will end on June 29, 2027.
What is an Emergency Use Authorization (EUA)?
An EUA is a legal mechanism that allows the FDA to authorize medical products during public health emergencies before they receive full regulatory approval.
Why is HHS ending the EUA declarations?
The department says the public health circumstances that existed during the COVID-19 pandemic have improved enough that emergency regulatory powers are no longer necessary for these product categories.
Will COVID-19 medicines still be available?
Yes. FDA-approved COVID-19 medicines and products will continue to be available. The announcement concerns the emergency authorization framework, not the withdrawal of approved products.
Will COVID-19 vaccines be affected?
The announcement specifically addresses certain drugs, biological products, and medical devices under emergency declarations. Products that already have full FDA approval remain authorized under standard regulatory pathways.
What happens to products currently operating under an EUA?
Manufacturers have a transition period before the declarations expire. They may seek full FDA approval or comply with other applicable regulatory requirements.
Does this mean COVID-19 is no longer a health concern?
No. The decision reflects that emergency conditions no longer justify special authorization procedures. COVID-19 continues to exist, but the government is shifting toward routine regulatory oversight.
Who announced the policy?
The announcement was made by the U.S. Department of Health and Human Services under the leadership of Secretary Robert F. Kennedy Jr.
Will hospitals need to change how they treat COVID-19 patients?
Hospitals can continue using FDA-approved treatments and medical devices. The primary change involves how future products are authorized rather than current standards of patient care.
Does this affect future public health emergencies?
No. If another qualifying public health emergency arises, federal law still allows the government to consider new Emergency Use Authorizations where appropriate.
Why is this HHS decision important?
The announcement marks another major transition away from pandemic-era emergency policies and signals a return to standard FDA regulatory processes for many COVID-19 medical products.